Hyperleptinemia in obese state renders luminal breast cancers refractory to tamoxifen by coordinating a crosstalk between Med1, miR205 and ErbB.
Journal
NPJ breast cancer
ISSN: 2374-4677
Titre abrégé: NPJ Breast Cancer
Pays: United States
ID NLM: 101674891
Informations de publication
Date de publication:
13 Aug 2021
13 Aug 2021
Historique:
received:
06
01
2021
accepted:
26
07
2021
entrez:
14
8
2021
pubmed:
15
8
2021
medline:
15
8
2021
Statut:
epublish
Résumé
Obese women with hormone receptor-positive breast cancer exhibit poor response to therapy and inferior outcomes. However, the underlying molecular mechanisms by which obesity/hyperleptinemia may reduce the efficacy of hormonal therapy remain elusive. Obese mice with hyperleptinemia exhibit increased tumor progression and respond poorly to tamoxifen compared to non-obese mice. Exogenous leptin abrogates tamoxifen-mediated growth inhibition and potentiates breast tumor growth even in the presence of tamoxifen. Mechanistically, leptin induces nuclear translocation of phosphorylated-ER and increases the expression of ER-responsive genes, while reducing tamoxifen-mediated gene repression by abrogating tamoxifen-induced recruitment of corepressors NCoR, SMRT, and Mi2 and potentiating coactivator binding. Furthermore, in silico analysis revealed that coactivator Med1 potentially associates with 48 (out of 74) obesity-signature genes. Interestingly, leptin upregulates Med1 expression by decreasing miR-205, and increases its functional activation via phosphorylation, which is mediated by activation of Her2 and EGFR. It is important to note that Med1 silencing abrogates the negative effects of leptin on tamoxifen efficacy. In addition, honokiol or adiponectin treatment effectively inhibits leptin-induced Med1 expression and improves tamoxifen efficacy in hyperleptinemic state. These studies uncover the mechanistic insights how obese/hyperleptinemic state may contribute to poor response to tamoxifen implicating leptin-miR205-Med1 and leptin-Her2-EGFR-Med1 axes, and present bioactive compound honokiol and adipocytokine adiponectin as agents that can block leptin's negative effect on tamoxifen.
Identifiants
pubmed: 34389732
doi: 10.1038/s41523-021-00314-9
pii: 10.1038/s41523-021-00314-9
pmc: PMC8363746
doi:
Types de publication
Journal Article
Langues
eng
Pagination
105Subventions
Organisme : NCI NIH HHS
ID : R01 CA204555
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R01CA204555
Organisme : Breast Cancer Research Foundation (BCRF)
ID : 90047965
Informations de copyright
© 2021. The Author(s).
Références
Clin Cancer Res. 2004 Jul 1;10(13):4325-31
pubmed: 15240518
Mol Cell. 2005 Jul 1;19(1):89-100
pubmed: 15989967
Br J Cancer. 2009 Feb 24;100(4):578-82
pubmed: 19223908
Endocr Relat Cancer. 2006 Jun;13(2):629-40
pubmed: 16728588
Biomed Pharmacother. 2013 Feb;67(1):22-30
pubmed: 23199901
Cancer Res. 2008 Dec 1;68(23):9712-22
pubmed: 19047149
Oncogene. 2009 Jul 23;28(29):2621-33
pubmed: 19483724
Adv Protein Chem Struct Biol. 2019;116:135-170
pubmed: 31036290
Nature. 2002 May 30;417(6888):563-7
pubmed: 12037571
Breast Cancer Res Treat. 2012 Apr;132(3):993-1000
pubmed: 21750966
Neoplasia. 2013 Jan;15(1):23-38
pubmed: 23358729
J Mol Med (Berl). 2010 Jul;88(7):677-86
pubmed: 20339829
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
J Biol Chem. 2012 Mar 9;287(11):8598-612
pubmed: 22270359
Endocr Relat Cancer. 2011 Jul 01;18(4):413-28
pubmed: 21555376
Int J Cancer. 2008 Nov 1;123(9):2188-94
pubmed: 18711698
J Biol Chem. 2003 Sep 12;278(37):35501-7
pubmed: 12816951
Cell Signal. 2010 Sep;22(9):1350-62
pubmed: 20466060
ACS Nano. 2017 Jan 24;11(1):335-346
pubmed: 27966906
J Natl Cancer Inst. 2009 Dec 16;101(24):1725-9
pubmed: 19940281
Int J Mol Sci. 2019 May 22;20(10):
pubmed: 31121868
Cancers (Basel). 2020 Dec 16;12(12):
pubmed: 33339340
Breast Cancer. 2021 Jan;28(1):25-39
pubmed: 33237347
Breast Cancer Res. 2007;9(6):R91
pubmed: 18162139
Mol Oncol. 2013 Jun;7(3):379-91
pubmed: 23228483
Nature. 2020 Jul;583(7817):620-624
pubmed: 32669709
Oncogene. 2017 Oct 12;36(41):5709-5721
pubmed: 28581518
Mol Oncol. 2014 May;8(3):565-80
pubmed: 24508063
Nat Protoc. 2015 Jun;10(6):823-44
pubmed: 25950236
Oncotarget. 2015 Jun 30;6(18):16396-410
pubmed: 26036628
Breast Cancer Res. 2005;7(5):R753-64
pubmed: 16168121
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Biochem Mol Toxicol. 2020 Nov;34(11):e22567
pubmed: 32729651
Clin Cancer Res. 2006 Mar 1;12(5):1447-53
pubmed: 16533767
Cancer Prev Res (Phila). 2017 Sep;10(9):494-506
pubmed: 28864539
J Biol Chem. 2007 May 4;282(18):13316-25
pubmed: 17344214
Cancer. 2012 Dec 1;118(23):5937-46
pubmed: 22926690
Metabolism. 2019 Mar;92:121-135
pubmed: 30445141
Cancer Res. 2015 Jun 1;75(11):2375-2386
pubmed: 25840984
Proc Natl Acad Sci U S A. 1999 Sep 14;96(19):10848-53
pubmed: 10485914
J Mammary Gland Biol Neoplasia. 2013 Dec;18(3-4):309-20
pubmed: 24214584
Int J Mol Sci. 2020 May 27;21(11):
pubmed: 32471192
Cancer Res. 2014 May 1;74(9):2617-29
pubmed: 24732433
Oncol Rep. 2008 Apr;19(4):905-11
pubmed: 18357374
BMC Biotechnol. 2011 Oct 05;11:90
pubmed: 21974986
Oncotarget. 2015 Oct 6;6(30):29947-62
pubmed: 26359358
Carcinogenesis. 2012 Apr;33(4):918-30
pubmed: 22345290
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6765-70
pubmed: 20351249
Mol Cell Endocrinol. 2015 Dec 15;418 Pt 3:264-72
pubmed: 25597633
Mol Cell Biol. 2005 Dec;25(24):10695-710
pubmed: 16314496
J Natl Cancer Inst. 2003 Oct 1;95(19):1467-76
pubmed: 14519753
Endocr Relat Cancer. 2011 Jan 19;18(1):R1-14
pubmed: 21149515
Endocr Connect. 2019 Nov;8(11):1539-1552
pubmed: 31671408
Proc Natl Acad Sci U S A. 2011 Feb 1;108(5):2058-63
pubmed: 21233418
NPJ Breast Cancer. 2019 Oct 2;5:33
pubmed: 31602394
Mol Endocrinol. 1997 Aug;11(9):1319-31
pubmed: 9259322